bioRxiv Science⌕ Search

Biology subjects

Moosa, A.

Publications and source records attributed to Moosa, A..

3 recordsLinked to original sources

Culture filtrate selectively promotes Mycobacterium tuberculosis growth from extremely low density inocula: implications for quantifying differentially culturable phenotypes

Differentially culturable (DC) Mycobacterium tuberculosis (Mtb) phenotypes reduce the sensitivity of sputum culture and may be associated with adverse treatment outcomes among tuberculosis patients. Accurately quantifying DC Mtb remains an important research objective, with current approaches tending to combine Most Probable Number (MPN) assays and culture filtrate (CF) supplementation. These assume that growth is equiprobable across all bacterial inoculum densities - an untested assumption for Mtb. We performed a half-logarithmic dilution series of Mtb from 70,000-0 CFU/mL, culturing each inoculum in either standard 7H9 or CF and monitoring growth by optical density. Inocula of [≥]2,000 CFU/mL were 33 times more likely to grow than inocula of [≤]700 CFU/mL. CF increased the odds of growth five-fold, and reduced the time-to-positivity by 294 hours ([~]12 days) compared to 7H9 alone. However, CFs growth-promoting effects diminished with increasing inoculum density, becoming negligible at 70,000 CFU/mL. Notably, CF broadly altered Mtb cell physiology, producing shorter bacilli that were less likely to incorporate the mycomembrane probe, DMN-trehalose. These data indicate that Mtb is poorly culturable from low inoculum densities - a limitation only partially overcome by CF. This non-uniform growth probability suggests that unsupplemented MPN assays may systematically underestimate Mtb CFU. Moreover, while CF promotes Mtb growth, its density-dependent activity and broader effects on cell physiology suggest that its influence extends beyond simply resuscitating DC Mtb. Improved methods are needed for detecting DC Mtb phenotypes, as these may support clinical care and shed light on factors that govern mycobacterial replication at different population densities. HighlightsO_LIMycobacterium tuberculosis (Mtb) culturability decreases at low inoculum densities C_LIO_LIMost Probable Number (MPN) assays may systematically underestimate Mtb CFUs C_LIO_LICulture filtrate (CF) selectively promotes Mtb growth from low densities C_LIO_LIMtb requires secreted factors in culture filtrate to initiate growth at low cell numbers C_LIO_LICF-supplemented MPN assays may be inadequate for detecting DC Mtb phenotypes C_LI

microbiology↗

Fusidic acid-based drug combinations exhibit enhanced activity against Mycobacterium tuberculosis

Tuberculosis (TB) imposes a major burden on global public health which is exacerbated by the escalating number of multidrug-resistant (MDR)-TB cases. There is consequently an urgent need for new anti-TB drugs and combination regimens. We have investigated the natural product antibiotic fusidic acid (FA) for repurposing against Mycobacterium tuberculosis, the causative agent of TB. Here, we report the results of synergy screens combining FA with a panel of approved anti-TB agents. Checkerboard and time-kill kinetics assays identified seven compounds from different chemical classes that synergized with FA in inhibiting the growth of M. tuberculosis in vitro: rifampicin (RIF), a rifamycin and frontline anti-TB drug; the macrolides, erythromycin (ERY), clarithromycin (CLR), and roxythromycin (ROX); the oxazolidinone, linezolid (LZD); the aminoglycoside, streptomycin (STR); and the aminocyclitol, spectinomycin (SPC). Among these, the strongest synergies were observed where FA was combined with SPC and ERY. Moreover, the FA-RIF combination was cidal, while all other FA combinations were bacteriostatic. These results provide in vitro evidence of the potential utility of FA-containing combinations against M. tuberculosis.

microbiology↗

Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis

Tuberculosis (TB) is a leading global cause of mortality owing to an infectious agent, accounting for almost one-third of antimicrobial resistance (AMR) deaths annually. We aimed to identify synergistic anti-TB drug combinations with the capacity to restore therapeutic efficacy against drug-resistant mutants of the causative agent, Mycobacterium tuberculosis. We investigated combinations containing the known translational inhibitors, spectinomycin (SPT) and fusidic acid (FA), or the phenothiazine, chlorpromazine (CPZ), which disrupts mycobacterial energy metabolism. Potentiation of whole-cell drug efficacy was observed in SPT-CPZ combinations. This effect was lost against an M. tuberculosis mutant lacking the major facilitator superfamily (MFS) efflux pump, Rv1258c. Notably, the SPT-CPZ combination restored SPT efficacy against an SPT-resistant mutant carrying a g1379t point mutation in rrs, encoding the mycobacterial 16S ribosomal RNA. Combinations of SPT with FA, which targets the mycobacterial elongation factor G, exhibited potentiating activity against wild-type M. tuberculosis. Moreover, this combination produced a marginal potentiating effect against both FA-monoresistant and SPT-monoresistant mutants. Finally, combining SPT with the frontline anti-TB agents, rifampicin (RIF) and isoniazid, resulted in enhanced activity in vitro and ex vivo against both drug-susceptible M. tuberculosis and a RIF-monoresistant rpoB S531L mutant.These results support the utility of novel potentiating drug combinations in restoring antibiotic susceptibility of M. tuberculosis strains carrying genetic resistance to any one of the partner compounds.

microbiology↗